crizotinib - Robuta Search

https://adisinsight.springer.com/drugsafety/803205989?error=cookies_not_supported&code=43036ece-3f5c-403e-9bd2-dc65459e4b64 Crizotinib - AdisInsight In a study, 2 patients [exact ages and sexes not stated] were described, who developed oesophageal ulcer and myelosuppression [durations of treatments to crizotinib adisinsight https://www.sciencedaily.com/releases/2013/11/131121091213.htm New crizotinib side-effect: Reduced measures of kidney function during treatment | ScienceDaily A study shows that using crizotinib to treat ALK positive non-small cell lung cancer (NSCLC) appears to reduce kidney function when assessed by one of the most... side effect https://scholars.duke.edu/publication/1234809 Scholars@Duke publication: Crizotinib Inhibits Hyperpolarization-activated Cyclic Nucleotide-Gated... scholars duke publication crizotinib activated https://adisinsight.springer.com/trials/700270993?error=cookies_not_supported&code=cc6c5139-f0bc-4dbc-84b9-1dfa15dea933 A phase 1B study of crizotinib either in combination or as single agent in pediatric patients with... This phase 1B study is investigating crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies. https://adisinsight.springer.com/drugsafety/803386138?error=cookies_not_supported&code=26ccd1cc-c5ff-4518-bdc2-c1dfcfea1f0b Crizotinib - AdisInsight In a retrospective study, a 61-year-old woman and a 44-year-old man were described, of whom, the woman experienced nausea, whereas the man experienced hepatic crizotinib adisinsight https://www.sciencedaily.com/releases/2017/01/170111102953.htm Bronchial carcinoma: Added benefit of crizotinib not proven | ScienceDaily The dossier contains no data or no suitable data on ROS1-positive, advanced non-small cell lung cancer. Results on ALK-positive tumors are not applicable. added benefit bronchial carcinoma crizotinib proven https://www.news-medical.net/news/20160411/Added-benefit-of-crizotinib-drug-for-first-line-treatment-of-advanced-bronchial-carcinoma-not-proven.aspx Added benefit of crizotinib drug for first-line treatment of advanced bronchial carcinoma not proven Jun 20, 2019 - The drug crizotinib (trade name: Xalkori) has been available since 2012 for patients with advanced non-small cell lung cancer (bronchial carcinoma) who have a... https://adisinsight.springer.com/drugsafety/803722964?error=cookies_not_supported&code=1fbf2ef0-636b-476d-8d1d-c7398284b542 Ceritinib/crizotinib - AdisInsight A 53-year-old woman developed acquired resistance during treatment with crizotinib for non-small cell lung cancer (NSCLC). Additionally, she exhibited no ceritinib crizotinib adisinsight https://pure.psu.edu/en/publications/response-to-crizotinib-in-ros1-rearranged-non-small-cell-lung-can/ Response to crizotinib in ROS1-rearranged non-small-cell lung cancer - Penn State small cell lung cancer https://www.semanticscholar.org/topic/crizotinib-250-MG-Oral-Capsule/10973153 crizotinib 250 MG Oral Capsule | Semantic Scholar crizotinib mg oral capsule semantic https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-crizotinib-pd0325901-binimetinib-for-bowel-cancer-mercuric1 A trial looking at crizotinib, PD-0325901 and binimetinib (MErCuRIC1) This trial is looking at drugs called crizotinib (also known as PF-02341066), PD-0325901 and binimetinib (also known as MEK162). looking at trial crizotinib pd binimetinib https://pubmed.ncbi.nlm.nih.gov/31078629/ A Complex Renal Cyst in a Patient on Crizotinib: Case Report A Complex Renal Cyst in a Patient on Crizotinib: Case Report in patient complex renal cyst crizotinib https://pubmed.ncbi.nlm.nih.gov/29403310/ The role of brigatinib in crizotinib-resistant non-small cell lung cancer Despite the advances in new targeted therapies in ALK positive population, most patients progress under ALK inhibitors within first 2 years; being the brain... the role https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT02201992&r=1 Crizotinib in Treating Patients with Stage IIA-IIIB Non-small Cell Lung Cancer That Has Been... Crizotinib in Treating Patients with Stage IIA-IIIB Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST... https://pubmed.ncbi.nlm.nih.gov/33172113/ Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and... The treatment of patients affected by non-small cell lung cancer (NSCLC) has been revolutionised by the discovery of druggable mutations. ROS1 (c-ros oncogene)... small cell lung cancer https://adisinsight.springer.com/drugsafety/803925636?error=cookies_not_supported&code=2a8fc120-f7c8-4d51-950e-54292396a566 Crizotinib - AdisInsight Twenty-eight patients with advanced non-small cell lung cancer (NSCLC) harbouring ROS1 rearrangement experienced lack of efficacy during treatment with crizotinib adisinsight https://pubmed.ncbi.nlm.nih.gov/26958511/ Metachronous primary uterine cancer surgically resected during Crizotinib treatment in a... Rearrangements of the anaplastic lymphoma kinase (ALK) gene are present in 3% to 7% of non-small-cell lung cancers (NSCLCs). Patients harboring ALK... uterine cancer primary https://boris-portal.unibe.ch/entities/publication/24172947-cd3f-4e9f-acc1-50a873abb233 Prolonged Response to Afatinib and Crizotinib in a Rare Case of EGFR-, HER2-, MET- and... We present the case of a 70-year-old never-smoking female patient with epidermal growth factor receptor (EGFR) p.L858R-mutated metastatic non-small cell lung... https://adisinsight.springer.com/trials/700313777?error=cookies_not_supported&code=7a87f432-2d1a-4f32-9ba6-2b8b10c476d4 To study correlation of molecular characteristics and clinical outcomes to crizotinib in... To study the correlation charactersitcs and clinical outcomes to crizotinib in ALK-positive patients to study clinical outcomes correlation molecular https://pubmed.ncbi.nlm.nih.gov/33685866/ Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung...